Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 3
2007 1
2008 2
2010 1
2011 4
2012 4
2013 5
2014 5
2015 4
2016 5
2017 5
2018 5
2019 4
2020 3
2021 3
2022 4
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Results by year
Filters applied: . Clear all
Page 1
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Pirrone I, Farruggia P, Cacciatore F, Giambona A, Guarina A, Marcello AP, Mosa C, Scalzo S, D'Angelo P. Pirrone I, et al. J Pediatr Hematol Oncol. 2021 Aug 1;43(6):e886-e890. doi: 10.1097/MPH.0000000000001979. J Pediatr Hematol Oncol. 2021. PMID: 33122582 Review.
Rasburicase is a recombinant urate oxidase enzyme indicated for tumor lysis syndrome, a potential life-threatening oncologic emergency that occurs most commonly during initial chemotherapy for hematological malignancies. As a result of the defects in the physiological anti
Rasburicase is a recombinant urate oxidase enzyme indicated for tumor lysis syndrome, a potential life-threatening oncologic emergenc
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Madanat L, Schoenherr D, Wey E, Gupta R. Madanat L, et al. BMJ Case Rep. 2021 Mar 16;14(3):e240967. doi: 10.1136/bcr-2020-240967. BMJ Case Rep. 2021. PMID: 33727299
Seven days after admission, she passed away due to subsequent complications; hence, follow-up G6PD level could not be obtained. Haemolytic anaemia and methemoglobinemia in the setting of recent rasburicase administration should raise clinical suspicion for G6PD defi …
Seven days after admission, she passed away due to subsequent complications; hence, follow-up G6PD level could not be obtained. Haemolytic a …
Rasburicase-Induced Methemoglobinemia.
Ahmed M, Sanchez T, Norgbe S, Picking CR, Millner PG. Ahmed M, et al. Cureus. 2021 Apr 10;13(4):e14406. doi: 10.7759/cureus.14406. Cureus. 2021. PMID: 33987056 Free PMC article.
Rasburicase is a recombinant urate-oxidase enzyme used in the prevention of tumor lysis syndrome. Methemoglobinemia can occur as a rare complication of treatment with rasburicase, primarily in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Rasburicase is a recombinant urate-oxidase enzyme used in the prevention of tumor lysis syndrome. Methemoglobinemia can occur
Rasburicase Therapy and G6PD and CYB5R Genotype.
Dean L, Kane M. Dean L, et al. 2020 Sep 29. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2020 Sep 29. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 32997466 Free Books & Documents. Review.
However, they are at risk of life-threating hemolytic reactions and methemoglobinemia if given oxidizing drugs such as rasburicase. Rasburicase is contraindicated in individuals with G6PD deficiency. ...The drug label states it is not known whether individual …
However, they are at risk of life-threating hemolytic reactions and methemoglobinemia if given oxidizing drugs such as rasburicase
Rasburicase induced methemoglobinemia: A systematic review of descriptive studies.
Vidhyashree BH, Zuber M, Taj S, Venkataraman R, Sathish Kumar BP, Jabeen N. Vidhyashree BH, et al. J Oncol Pharm Pract. 2022 Feb 4:10781552221075239. doi: 10.1177/10781552221075239. Online ahead of print. J Oncol Pharm Pract. 2022. PMID: 35119341
PURPOSE: There is an increased number of reports being published on rasburicase-induced methemoglobinemia recently. We aimed to identify and critically evaluate all the descriptive studies that described the rasburicase-induced methemoglobinemia, its t …
PURPOSE: There is an increased number of reports being published on rasburicase-induced methemoglobinemia recently. We aimed t …
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Raru Y, Abouzid M, Parsons J, Zeid F. Raru Y, et al. Respir Med Case Rep. 2018 Dec 23;26:142-145. doi: 10.1016/j.rmcr.2018.12.011. eCollection 2019. Respir Med Case Rep. 2018. PMID: 30603605 Free PMC article.
Rasburicase is a recombinant urate-oxidase enzyme and is a very important medication for tumor lysis syndrome. Methemoglobinemia and hemolysis are known side effects of rasburicase that result from oxidative stress caused by hydrogen peroxide, a byproduct gen
Rasburicase is a recombinant urate-oxidase enzyme and is a very important medication for tumor lysis syndrome. Methemoglobinemia
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency.
Khan M, Paul S, Farooq S, Oo TH, Ramshesh P, Jain N. Khan M, et al. Curr Drug Saf. 2017;12(1):13-18. doi: 10.2174/1574886312666170111151246. Curr Drug Saf. 2017. PMID: 28078984 Review.
Methemoglobinemia is a serious rare adverse effect of rasburicase, more common in patients with G6PD deficiency. ...RESULTS: Rasburicase-induced methemoglobinemia is more common in patients with G6PD deficiency, and rasburicase is therefore cont
Methemoglobinemia is a serious rare adverse effect of rasburicase, more common in patients with G6PD deficiency. ...RESULTS:
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Sherwood GB, Paschal RD, Adamski J. Sherwood GB, et al. Clin Case Rep. 2016 Feb 3;4(4):315-9. doi: 10.1002/ccr3.495. eCollection 2016 Apr. Clin Case Rep. 2016. PMID: 27099716 Free PMC article.
Rasburicase for the treatment of tumor lysis syndrome has been associated with hemolytic anemia and methemoglobinemia, usually in patients with G6PD deficiency. Risks and benefits should be considered prior to use of rasburicase in at-risk patients. Methylene
Rasburicase for the treatment of tumor lysis syndrome has been associated with hemolytic anemia and methemoglobinemia, usually
Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.
Ibrahim U, Saqib A, Mohammad F, Atallah JP, Odaimi M. Ibrahim U, et al. J Oncol Pharm Pract. 2018 Jun;24(4):309-313. doi: 10.1177/1078155217701295. Epub 2017 Mar 26. J Oncol Pharm Pract. 2018. PMID: 28345492
Rasburicase is indicated for the prevention and treatment of tumor lysis syndrome which can be a potentially life-threatening emergency. ...Patients with glucose-6-phosphate dehydrogenase enzyme deficiency are at high risk of methemoglobinemia from oxidizing agents.
Rasburicase is indicated for the prevention and treatment of tumor lysis syndrome which can be a potentially life-threatening emergen
Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review.
Ng JS, Edwards EM, Egelund TA. Ng JS, et al. J Oncol Pharm Pract. 2012 Dec;18(4):425-31. doi: 10.1177/1078155211429385. Epub 2011 Dec 21. J Oncol Pharm Pract. 2012. PMID: 22190578
Descriptions of the clinical course should it happen are limited in the literature. There are eight reported cases of rasburicase-related methemoglobinemia, with or without hemolytic anemia, in the literature of which five are pediatric patients. ...We are reporting …
Descriptions of the clinical course should it happen are limited in the literature. There are eight reported cases of rasburicase-rel …
49 results